Fiocruz Ushers in a New Chapter for SMA Treatment with GB221 Gene Therapy Trial

The Fundação Oswaldo Cruz (Fiocruz), Brazil's premier public health research powerhouse, has marked a historic milestone by dosing the first patient in the CHARISMA clinical trial for GB221, an innovative gene therapy targeting Spinal Muscular Atrophy type 1 (SMA1). Announced in late February 2026, this Phase 1/2 study represents Brazil's bold step into next-generation advanced therapies, potentially transforming lives for infants born with this devastating genetic disorder. With government backing exceeding R$122 million, the initiative underscores Fiocruz's commitment to making cutting-edge treatments accessible through the Sistema Único de Saúde (SUS).

Coordinated by experts from the Casa dos Raros and conducted at the Hospital de Clínicas de Porto Alegre (HCPA), affiliated with Universidade Federal do Rio Grande do Sul (UFRGS), the trial's launch highlights deep ties between Fiocruz and Brazil's academic institutions. The first infant patient received a single intracisterna magna (ICM) dose in January 2026, initiating a rigorous evaluation of safety, tolerability, and early efficacy signals.

Demystifying Spinal Muscular Atrophy: Genetics, Impact, and Burden in Brazil

Spinal Muscular Atrophy (SMA) is a rare autosomal recessive neuromuscular disorder caused by mutations or deletions in the SMN1 gene on chromosome 5, which encodes the Survival Motor Neuron (SMN) protein essential for lower motor neuron survival. Without sufficient SMN protein, progressive degeneration occurs, leading to muscle weakness, respiratory failure, and early mortality in severe cases.

SMA manifests in four main types based on onset and severity. Type 1 (Werdnig-Hoffmann disease), the focus of the GB221 trial, strikes before six months, confining infants to never sitting independently without support. Brazil sees an estimated 1 in 9,000 to 10,000 live births affected by SMA, translating to roughly 300 new cases annually, with SMA1 comprising about 50%. The disease's toll is profound: untreated SMA1 infants rarely survive beyond two years, imposing immense emotional and economic strain on families and the health system.

Early newborn screening, piloted in states like Paraná and São Paulo through university-led programs at Universidade Estadual de Campinas (Unicamp) and Universidade de São Paulo (USP), has boosted diagnosis rates, yet access remains uneven outside urban centers.

From Spinraza to Zolgensma: Brazil's Journey with Existing SMA Therapies

Prior to gene therapy, SMA management relied on supportive care and disease-modifying treatments (DMTs). Nusinersen (Spinraza), an antisense oligonucleotide boosting SMN2 exon 7 inclusion, requires lifelong intrathecal injections. Risdiplam (Evrysdi), an oral SMN2 splicing modifier, offers daily dosing convenience. Zolgensma (onasemnogene abeparvovec), the first approved AAV9-based SMN1 gene therapy via intravenous infusion, delivers transformative one-time results but costs up to R$12 million per dose—prohibitively high for SUS without judicial mandates.

Fiocruz, partnering with Hypera Pharma, is now locally producing Spinraza, slashing costs and enhancing supply security. This groundwork paves the way for GB221, promising even greater efficacy via targeted CNS delivery while circumventing AAV9 immunity issues prevalent in adults.

For those pursuing careers in neuromuscular research, opportunities abound in higher-ed research jobs at institutions like Fiocruz and affiliated universities.

GB221 Decoded: Engineering a Safer, More Potent SMA Gene Therapy

Developed by GEMMABio under gene therapy pioneer James M. Wilson (University of Pennsylvania), GB221 employs the AAVhu68 capsid for superior CNS tropism and a codon-optimized SMN1 transgene in a refined cassette minimizing overexpression toxicities observed in earlier therapies like Zolgensma, such as dorsal root ganglion pathology.

The step-by-step process: (1) Patient screening confirms SMN1 biallelic mutations and absence of neutralizing antibodies; (2) ICM injection under imaging guidance delivers the vector-laden SMN1 gene directly to cerebrospinal fluid, transducing motor neurons efficiently; (3) Sustained SMN expression halts degeneration and promotes regeneration; (4) Monitoring tracks motor milestones (e.g., sitting, standing), biomarkers, and adverse events.

Preclinical rodent and non-human primate data showed robust SMN restoration with reduced immunogenicity, positioning GB221 as a leap forward.

Photo by Logan Voss on Unsplash

Unpacking the CHARISMA Trial: Protocol, Endpoints, and Expansion Plans

Registered as NCT07070999, CHARISMA is a multicenter, open-label Phase 1/2 trial enrolling up to 18 infants aged 2 weeks to under 12 months—symptomatic SMA1 and presymptomatic siblings. Primary endpoints focus on safety (e.g., no vector-related hepatotoxicity) and tolerability up to 52 weeks; secondary include CHOP-INTEND scores, event-free survival, and ventilation independence.

• Phase 1: Dose escalation in 3-6 patients, first cohort complete with the inaugural dosing.
• Phase 2: Efficacy expansion, potentially adding sites like HC-Unicamp.
• Timeline: Follow-up to 5 years, with Brazil as Latin American hub for further recruitment.

Intrials oversees operations, ensuring GCP compliance.

Fiocruz and Bio-Manguinhos: Architects of Brazil's Gene Therapy Sovereignty

Fiocruz's Bio-Manguinhos, a global vaccine leader (e.g., COVID-19 tech transfer from AstraZeneca), spearheads viral vector mastery. The GEMMABio partnership includes full technology transfer for domestic GB221 production, targeting 20-25% of U.S. costs—critical for SUS scalability.

This aligns with Fiocruz's Advanced Therapies Strategy, fostering a Complexo Econômico-Industrial da Saúde ecosystem. President Mario Moreira emphasizes, "This opens pathways for innovative gene therapies in SUS for the first time."

Brazilian Universities Fueling the Gene Therapy Revolution

HCPA-UFRGS and HC-Unicamp anchor the trial, leveraging robust graduate programs. UFRGS's Postgraduate Program in Medical Genetics trains experts like coordinator Roberto Giugliani, MD, PhD, a doyen in rare diseases. Unicamp's biotech initiatives complement Fiocruz collaborations.

Other leaders: USP's Vector Core produces AAVs; UFRJ and UFMG pioneer CAR-T and stem cells. Fiocruz's own master's/PhD in Immunobiological Technology nurtures talent. These programs produce researchers advancing Brazil's 30% annual gene therapy market growth projection to 2027.

Prospective students can explore scholarships for biotech studies or research assistant jobs.

Overcoming Hurdles: Regulatory, Ethical, and Logistical Challenges

ANVISA's priority review exemplifies Brazil's agile framework, yet scalability demands infrastructure. Ethical considerations include informed consent for presymptomatic infants and long-term monitoring. Fiocruz addresses equity via SUS integration, countering judicialization burdens (over 100 Zolgensma cases).

Photo by Logan Voss on Unsplash

Patient Perspectives and Real-World Impacts

Early anecdotes from similar therapies show infants achieving milestones like head control within months. Jonas Saute, UFRGS professor, notes ICM delivery suits seropositive patients. Families via Casa dos Raros hail it as hope incarnate.

Broader: ~1,500 Brazilians live with SMA; success could model therapies for 13 million rare disease patients.

Looking Ahead: Scaling Gene Therapies and Training the Next Generation

Post-CHARISMA, Fiocruz eyes Phase 3 and multi-product pipelines. Universities ramp up curricula: UFRGS expands genetics fellowships; Unicamp invests in vector labs.

For career seekers, craft a winning academic CV for Brazil's booming biotech scene. Check university jobs and Brazil higher ed opportunities.

In summary, Fiocruz's SMA trial catalyzes Brazil's ascent in global gene therapy, blending public health prowess with academic innovation for equitable futures.